Here's how it works
01. Edit your form online
Type text, add images, blackout confidential details, add comments, highlights and more.
02. Sign it in a few clicks
Draw your signature, type it, upload its image, or use your mobile device as a signature pad.
03. Share your form with others
Send it via email, link, or fax. You can also download it, export it or print it out.
How to use or fill out PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247
- Click ‘Get Form’ to open it in the editor.
- Begin with SECTION I – MEMBER INFORMATION. Enter the member's name, ID number, and date of birth clearly.
- Proceed to SECTION II – PRESCRIPTION INFORMATION. Fill in the date the prescription was written, prescriber's name, National Provider Identifier, address, and phone number.
- Indicate the member’s proposed hepatitis C drug treatment regimen by listing the drug names, whether currently taking them, daily doses, and expected duration.
- In SECTION III – CLINICAL INFORMATION, provide diagnosis codes and descriptions. Ensure to attach relevant medical records as specified.
- Complete any additional questions regarding previous treatments and conditions that may affect drug usage.
- Finally, sign in SECTION IV – AUTHORIZED SIGNATURE and include any additional information in SECTION V if necessary.
Start using our platform today for free to streamline your form completion process!
Fill out PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247 online
It's free
It's free
See more PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247 versions
We've got more versions of the PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247 form. Select the right PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247 version from the list and start editing it straight away!
Got questions?
We have answers to the most popular questions from our customers. If you can't find an answer to your question, please contact us.
Contact us
Can I use DocHub to create legal eSignatures on my PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247?
Yes, you can utilize DocHub for signing any business and private documentation, including your PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247. All eSignatures you create with our tool are legally binding and court-admissible, as DocHub complies with criteria required by ESIGN and UETA. Save your completed paperwork with a detailed Audit Trail if needed.
Can I print my PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247 and finish it on my own?
When you choose analog ways of completing your PRIOR AUTHORIZATION DRUG ATTACHMENT FOR HEPATITIS C AGENTS, F-01247, you can easily download your file for printing. Search DocHub’s Forms & Templates catalog to get the exact file template you need and open it for editing or download it on your gadget in the format of your liking. It is possible to complete your form electronically and place your handwritten signature on it right after printing or eSign your file with DocHub.
What drugs are FDA approved for hep C?
BACKGROUND: Mavyret, Zepatier, and Vosevi are FDA-approved to treat chronic hepatitis C in patients without liver impairment or with mild liver impairment (Child-Pugh A).
Is MAVYRET approved by the FDA?
With this approval, MAVYRET is the first and only DAA therapy approved to treat patients with acute HCV in eight weeks with a 96% cure rate. HCV is a highly infectious blood-borne disease affecting the liver. People recently infected, or those with acute HCV, may not have symptoms.
What is the oral drug for Hep C?
Ledipasvir/sofosbuvir (Harvoni) Ledipasvir inhibits HCV NS5A protein, which is required for viral replication. Sofosbuvir is an inhibitor of HCV NS5B RNA-dependent polymerase. The oral combination is indicated for treatment of adults with chronic hepatitis C infection with genotype 1, 4, 5, or 6.
Security and compliance
At DocHub, your data security is our priority. We follow HIPAA, SOC2, GDPR, and other standards, so you can work on your documents with confidence.
Learn more
People also ask
What is the FDA approved treatment for Hep C?
Mavyret, Vosevi, and Epclusa are all FDA-approved for the treatment of chronic (long-lasting) hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). In June 2025, Mavyret was also approved by the FDA to treat acute (recently infected) HCV.
What are Pangenotypic drugs for Hep C?
There are now three pan-genotypic DAA regimens listed on the PBS: sofosbuvir plus velpatasvir, glecaprevir plus pibrentasvir, and sofosbuvir plus velpatasvir plus voxilaprevir. The first-line regimens for treatment-naive people living with hepatitis C are sofosbuvir plus velpatasvir or glecaprevir plus pibrentasvir.
Which is better, Epclusa or MAVYRET?
When taken exactly as prescribed, both drugs are highly effective at curing this disease. Depending on your condition, you may only have to take Mavyret for 8 weeks compared with 12 weeks for Epclusa. However, your doctor may prescribe Epclusa if you have severe liver disease.
What is the new drug to cure hep C?
Medically reviewed by Leigh Ann Anderson, PharmD. Last updated on June 15, 2025. The newest drugs for the treatment of hepatitis C include Mavyret (glecaprevir and pibrentasvir), Vosevi (sofosbuvir, velpatasvir, and voxilaprevir), and Epclusa (sofosbuvir and velpatasvir).
